- Wall Street indices open mixed
- Russell 2000 drops below 50-session moving average
- Earnings reports from Eli Lilly, Coherent and Symbotic
Wall Street indices launched today's trading mixed - S&P 500 and Nasdaq gained slightly at session launch, while Dow Jones and small-cap Russell 2000 moved a touch lower. Economic calendar for today is empty and stock traders continue to focus on incoming earnings reports. Coherent (COHR.US) and Symbotic (SYM.US) are examples of stocks, which experience large post-earnings price moves today.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appSource: xStation5
Contrary to other major Wall Street indices, small-cap Russell 2000 continues to trade significantly below it's all-time highs. Taking a look at index futures chart (US2000) at D1 interval, we can see that bulls have recently failed to break above the 2,025 pts resistance zone, which marks the upper limit of the ongoing trading range. Index pulled back and is now testing the 1,945 pts swing area. A point to note is that price broke below the 50-session moving average (green line), which often acted as a support or resistance level for the index, and it hints that a deeper pullback may be looming. A near-term support level to watch can be found in the 1,920 pts.
Company News
Eli Lilly (LLY.US) is trading higher following the release of the Q4 2023 earnings report. Company reported a 28% YoY jump in revenue to $9.35 billion (exp. $8.96 billion), driven by sales of Mounjaro, Trulicity and Verzenio drugs. Research & Developments expenses also climbed 28% YoY to $2.56 billion (exp. $2.39 billion). Market, selling and administrative expenses increased 17% YoY to $1.92 billion (exp. $1.86 billion). Adjusted EPS came in at $2.49 (exp. $2.18). Company expects full-year revenue to reach $40.4-41.6 billion (exp. $39.5 billion) and adjusted EPS to reach $12.20-12.70 (exp. $12.56).
Coherent (COHR.US) rallies following releases of fiscal-Q2 2024 earnings (calendar October - December 2023 period). Revenue during the quarter declined 17% YoY to $1.13 billion (exp. $1.12 billion) while loss per share narrowed from $0.58 to $0.38. However, adjusted EPS came in at positive $0.36 and was better than $0.24 expected. Company expects fiscal-Q3 2024 revenue to reach $1.12-1.20 billion (exp. $1.17 billion) and adjusted EPS to reach $0.32-0.52 (exp. $0.37). Full-year fiscal-2024 revenue is expected at $4.55-4.70 billion, up from previous guidance of $4.50-4.70 billion.
Coherent (COHR.US) launched today's trading with a massive bullish price gap. Stock jumped above the $56.50 resistance zone at the opening and reached the highest level since mid-2023. The next potential resistance zone can be found in the $66.00 area. Source: xStation5
Symbotic (SYM.US) slumped at the launch of today's Wall Street cash session in response to fiscal-Q1 2024 earnings (calendar October - December 2023). Company reported revenue at $368.5 million (exp. $369.2 million) and adjusted EBITDA at $14.1 million (exp. $13.9 million). Loss per share came in at $0.02 and was slightly deeper than expected. Company's cash position increased 88% QoQ to $486 million (exp. 369 million). While fiscal-Q1 results were more or less in-line with expectations, Symbotic disappointed with fiscal-Q2 guidance. Company expects fiscal-Q2 revenue at $400-420 million (exp. $405 million) and adjusted EBITDA at $12-15 million (exp. $25.2 million).
Analysts' actions
- Tesla (TSLA.US) downgraded to "neutral" at Daiwa. Price target set at $195.00
- Bristol-Myers Squibb (BMY.US) downgraded to "neutral" at Redburn Atlantic. Price target set at $54.00
Symbotic (SYM.US) slumped at the launch of today's Wall Street cash session. Stock opened near the 200-session moving average (purple line) and is testing recent local lows in the $40.00 area. A break below this area would pave the way for a test of the $37.00 support zone. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
